This site is intended for healthcare professionals
Drug news

Positive results from Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan to treat HER2-positive, unresectable breast cancer . Daiichi Sankyo + AstraZeneca

Read time: 1 mins
Last updated:10th May 2019
Published:10th May 2019
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest